Literature DB >> 16336960

Overexpression of ADAM9 enhances growth factor-mediated recycling of E-cadherin in human colon cancer cell line HT29 cells.

Takafumi Hirao1, Daisuke Nanba, Motonari Tanaka, Hiroshi Ishiguro, Yumi Kinugasa, Yuichiro Doki, Masahiko Yano, Nariaki Matsuura, Morito Monden, Shigeki Higashiyama.   

Abstract

Growth factor-mediated stimulation of epithelial cells induces the disassembly of E-cadherin-mediated cell-cell adhesion. We found that overexpression of a disintegrin and metalloprotease 9 (ADAM9) enhanced growth factor-mediated induction of endocytosis and dynamic recycling of E-cadherin in HT29 human colon cancer cells. In addition, ubiquitination and degradation of E-cadherin were reduced in these cells. ADAM9 constitutively interacted with E-cadherin, and the two proteins co-localized at the plasma membrane of HT29 cells. Administration of a metalloprotease inhibitor or overexpression of an ADAM9 mutant lacking metalloprotease activity attenuated growth factor-dependent endocytosis and recycling of E-cadherin as well as scattering of HT29 cells. These results suggest that the metalloprotease activity of ADAM9 mediates growth factor-induced endocytosis and dynamic recycling of E-cadherin and prevents E-cadherin degradation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16336960     DOI: 10.1016/j.yexcr.2005.10.032

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  19 in total

1.  Secreted and membrane-bound isoforms of protease ADAM9 have opposing effects on breast cancer cell migration.

Authors:  Jessica L Fry; Alex Toker
Journal:  Cancer Res       Date:  2010-08-24       Impact factor: 12.701

Review 2.  Anchoring junctions as drug targets: role in contraceptive development.

Authors:  Dolores D Mruk; Bruno Silvestrini; C Yan Cheng
Journal:  Pharmacol Rev       Date:  2008-05-15       Impact factor: 25.468

Review 3.  Intercellular junction assembly, dynamics, and homeostasis.

Authors:  Kathleen J Green; Spiro Getsios; Sergey Troyanovsky; L M Godsel
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-02       Impact factor: 10.005

4.  Inhibition of ADAM9 expression induces epithelial phenotypic alterations and sensitizes human prostate cancer cells to radiation and chemotherapy.

Authors:  Sajni Josson; Cynthia S Anderson; Shian-Ying Sung; Peter A S Johnstone; Hiroyuki Kubo; Chia-Ling Hsieh; Rebecca Arnold; Murali Gururajan; Clayton Yates; Leland W K Chung
Journal:  Prostate       Date:  2011-02-15       Impact factor: 4.104

5.  The effect of disintegrin-metalloproteinase ADAM9 in gastric cancer progression.

Authors:  Jeong Min Kim; Hei-Cheul Jeung; Sun Young Rha; Eun Jeong Yu; Tae Soo Kim; You Keun Shin; Xianglan Zhang; Kyu Hyun Park; Seung Woo Park; Hyun Cheol Chung; Garth Powis
Journal:  Mol Cancer Ther       Date:  2014-10-24       Impact factor: 6.261

6.  Mapping transmembrane binding partners for E-cadherin ectodomains.

Authors:  Omer Shafraz; Bin Xie; Soichiro Yamada; Sanjeevi Sivasankar
Journal:  Proc Natl Acad Sci U S A       Date:  2020-11-23       Impact factor: 11.205

7.  EGFR and ADAMs cooperate to regulate shedding and endocytic trafficking of the desmosomal cadherin desmoglein 2.

Authors:  Jodi L Klessner; Bhushan V Desai; Evangeline V Amargo; Spiro Getsios; Kathleen J Green
Journal:  Mol Biol Cell       Date:  2008-11-05       Impact factor: 4.138

8.  MiR-126 regulated breast cancer cell invasion by targeting ADAM9.

Authors:  Cheng-Zheng Wang; Peng Yuan; Yin Li
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

9.  High expression of a disintegrin and metalloproteinase-9 predicts a shortened survival time in completely resected stage I non-small cell lung cancer.

Authors:  Jun Zhang; Juan Qi; Ning Chen; Weineng Fu; Baosen Zhou; Anguang He
Journal:  Oncol Lett       Date:  2013-02-22       Impact factor: 2.967

10.  ADAM9 is highly expressed in renal cell cancer and is associated with tumour progression.

Authors:  Florian R Fritzsche; Kirsten Wassermann; Monika Jung; Angelika Tölle; Ilka Kristiansen; Michael Lein; Manfred Johannsen; Manfred Dietel; Klaus Jung; Glen Kristiansen
Journal:  BMC Cancer       Date:  2008-06-26       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.